Osimertinib

You have access
Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety
TAKAE OKUNO, MASAFUMI HONGOH, RYOSUKE TANINO, TAMIO OKIMOTO, YUKARI TSUBATA and TAKESHI ISOBE

Anticancer Research June 2025, 45 (6) 2551-2561; DOI: https://doi.org/10.21873/anticanres.17627
You have access
EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment?
GIUSEPPINA IMPROTA, GIULIA VITA, ALFREDO TARTARONE, GIOVANNI CALICE, LUDMILA CARMEN OMER and ANGELA ZUPA

Anticancer Research January 2025, 45 (1) 335-340; DOI: https://doi.org/10.21873/anticanres.17421
You have access
Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data
SARAH SHARMAN MOSER, LIOR APTER, JOSIE SOLOMON, GABRIEL CHODICK, MIRIANA WOLLNER and NAVA SIEGELMANN-DANIELI

Anticancer Research January 2024, 44 (1) 257-265; DOI: https://doi.org/10.21873/anticanres.16809
You have access
Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell Lung Cancer Cell Line H1975
XUEXIA TONG, RUI ZHANG, RONG SUN, WEIZHI YANG, JINHAN SUN, JUAN CHEN and FANG LI

Anticancer Research December 2023, 43 (12) 5459-5474; DOI: https://doi.org/10.21873/anticanres.16749
You have access
YTHDF3 Modulates EGFR/ATK/ERK/p21 Signaling Axis to Promote Cancer Progression and Osimertinib Resistance of Glioblastoma Cells
HSUN-HUA LEE, CHING-CHUAN HSIEH, CHENG-CHIH CHANG, WAN-TING LIAO and HSIANG-CHENG CHI

Anticancer Research December 2023, 43 (12) 5485-5498; DOI: https://doi.org/10.21873/anticanres.16751
Open Access
Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With EGFR-mutated Lung Adenocarcinoma
SHIN ITO, KYOJI TSURUMI, NORIHISA SHINDO, SATOSHI SOMA, KAZUNORI YAMAGUCHI, KEIICHI TAMAI, MAI MOCHIZUKI, HARUNA FUJIMORI, MAMI MORITA, KANA WATANABE, AYA SUZUKI, TATSURO FUKUHARA and JUN YASUDA

Anticancer Research November 2023, 43 (11) 5031-5040; DOI: https://doi.org/10.21873/anticanres.16702
You have access
Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients
MASAAKI TANDA, KAZUHIRO YAMAMOTO, TOMOKI HORI, HIROKI NISHIGUCHI, MIKI YAGI, MICHIKO SHIMIZU, TORU KONISHI, TOMONORI OZAKI, NATSUE YOSHIOKA, MOTOKO TACHIHARA, TAKEFUMI ITO, SHIGEKI IKUSHIMA, TOMOHIRO OMURA and IKUKO YANO

Anticancer Research April 2023, 43 (4) 1775-1783; DOI: https://doi.org/10.21873/anticanres.16331
Open Access
Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer
MIZUKI YAMAZAKI, NAO KOMIZO, HIROTOSHI IIHARA, CHIEMI HIROSE, KOMEI YANASE, YUTO YAMADA, JUNKI ENDO, SHUJI YAMASHITA, YASUSHI OHNO, KENICHIRO TODOROKI, AKIO SUZUKI and HIDEKI HAYASHI

Anticancer Research February 2023, 43 (2) 725-732; DOI: https://doi.org/10.21873/anticanres.16211
Open Access
Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer
TOSHIHIRO SHIOZAWA, TAKESHI NUMATA, TOMOHIRO TAMURA, TAKEO ENDO, TAKAYUKI KABURAGI, YUSUKE YAMAMOTO, HIDEYASU YAMADA, NORIHIRO KIKUCHI, KAZUHITO SAITO, MASAHARU INAGAKI, KOICHI KURISHIMA, YASUNORI FUNAYAMA, KUNIHIKO MIYAZAKI, NOBUYUKI KOYAMA, KINYA FURUKAWA, HIROYUKI NAKAMURA, SHINJI KIKUCHI, HIDEO ICHIMURA, YUKIO SATO, IKUO SEKINE, HIROAKI SATOH and NOBUYUKI HIZAWA

Anticancer Research May 2022, 42 (5) 2583-2590; DOI: https://doi.org/10.21873/anticanres.15736
You have access
Real-world Afatinib Outcomes in Advanced Non–small Cell Lung Cancer Harboring EGFR Mutations
CHI-HAN CHEN, JOHN WEN-CHENG CHANG, CHING-FU CHANG, CHEN-YANG HUANG, CHENG-TA YANG, CHIH-HSI SCOTT KUO, YUEH-FU FANG, PING-CHIH HSU and CHIAO-EN WU

Anticancer Research April 2022, 42 (4) 2145-2157; DOI: https://doi.org/10.21873/anticanres.15697

Main menu

User menu

Search

Osimertinib

Pages